Sarepta Therapeutics Inc (SRPT) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Total Assets Chart for Sarepta Therapeutics Inc
Sarepta Therapeutics Inc (SRPT) total assets for FY2025 were USD 3.3B, a -15.5% change from FY2024. Sarepta Therapeutics Inc's total assets grew from USD 2.3M in 1995 to USD 3.3B in 2025 (145539.3% over 30 years). Total assets compound annual growth rate: 5-year CAGR of 2.3%, 10-year CAGR of 28.5%, 20-year CAGR of 22.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.87B
- Implied Share Price
- $17.73
- Enterprise Value
- $1.95B
- Revenue (TTM)
- $1.97B
- EBITDA
- -$17.53M
- Profit Margin
- -6.93%
- Trailing P/E
- —
- Forward P/E
- 5.08
- Price/Book (MRQ)
- 1.04
- Price/Sales (TTM)
- 0.95
- EV/EBITDA
- 16.91
- EV/Revenue
- 0.89
- Dividend Yield
- —
- Book Value
- $14.46
- Free Cash Flow (FY2025)
- -$307.45M
- Free Cash Flow Yield
- -16.42%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.